Docetaxel plus cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer progressing on 5-fluorouracil-based regimen

Citations

WEB OF SCIENCE

39
Citations

SCOPUS

46

초록

The purpose of this study was to determine the activity and safety of docetaxel plus cisplatin as second-line chemotherapy for advanced gastric cancer. This trial included patients who had failed first-line chemotherapy with a 5-fluorouracil regimen within I year before their enrollment. After registration, patients were treated with docetaxel intravenously at a dose of 60 mg/m(2) given over 1 hour followed by cisplatin 60 mg/m(2) given over 2 hours. The treatment was continued every 3 weeks until disease progression or unacceptable toxicity was detected. Forty-three patients were registered and 41 were assessable for response. Seven partial responses were observed (17.1% of the "evaluable" patients; 95% confidence interval [CI], 0-29) with a median response duration of 3.9 months. Stable disease was documented in 2 cases (4.9%). The median survival was 5.8 months (95% Cl, 3.4-8.3), resulting in a I-year survival rate of 23%. Tolerance was acceptable, with the main toxicity being neutropenia. The authors conclude that second-line chemotherapy with docetaxel plus cisplatin for advanced gastric cancer is feasible with an acceptable toxicity level.

키워드

docetaxel; cisplatin; adenocarcinoma; gastric; chemotherapy; COMBINATION CHEMOTHERAPY; DRUG-COMBINATION; SUPPORTIVE CARE; METHOTREXATE; FLUOROURACIL; DOXORUBICIN; CARCINOMA
제목
Docetaxel plus cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer progressing on 5-fluorouracil-based regimen
저자
Park, SH; Kang, WK; Lee, HR; Park, J; Lee, KE; Lee, SH; Park, JO; Kim, K; Kim, WS; Chung, CW; Im, YH; Lee, MH; Park, CH; Park, K
DOI
10.1097/01.coc.0000136018.81814.79
발행일
2004-10
유형
Article
저널명
American Journal of Clinical Oncology
권
27
호
5
페이지
477 ~ 480